Related Experiment Video

Updated: Jan 13, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.8K

Targeting cell cycle in leukemia: "Is palbociclib the game-changer?": A review

Muhamad Amir Azizan1, Zainul Abeden1, Nur Haida Natasha Shamsuddin1

  • 1Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia.

Medicine
|January 7, 2026
PubMed

Insights

Palbociclib, a CDK4/6 inhibitor, shows promise for leukemia treatment. This review analyzes its effectiveness and safety in preclinical and clinical studies for this complex cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Leukemia is a complex and heterogeneous cancer with limited treatment advancements.
  • Targeting molecular pathways offers a promising strategy for novel leukemia therapies.
  • Cyclin-dependent kinases (CDKs) are critical regulators of the cell cycle and are implicated in cancer progression.

Purpose of the Study:

  • To review the existing literature on palbociclib's efficacy and safety in leukemia.
  • To evaluate palbociclib as a therapeutic candidate targeting CDK4/6 in leukemia.
  • To explore the role of CDK6 in leukemic cells beyond cell cycle progression.

Main Methods:

  • Comprehensive literature analysis of preclinical and clinical studies.
  • Investigation of palbociclib's mechanism of action as a CDK4/6 inhibitor.
  • Assessment of palbociclib's efficacy as a monotherapy and in combination treatments.

Main Results:

  • Palbociclib targets CDK4/6, showing potential in leukemia treatment.
  • CDK6 plays crucial roles in leukemic cells, making it a significant therapeutic target.
  • Existing literature suggests palbociclib's effectiveness and safety profile warrants further investigation in leukemia.

Conclusions:

  • Palbociclib is a promising therapeutic agent for leukemia, particularly targeting CDK4/6.
  • Further clinical investigations are needed to establish palbociclib's role in leukemia treatment regimens.
  • Targeting CDK6 presents a viable strategy for developing novel leukemia therapies.
Keywords:
ALLAMLCDK4/6 inhibitorCDK6cell cycleleukemiapalbociclib

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.4K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
The Cell Cycle Control System02:11

The Cell Cycle Control System

The cell cycle is an organized set of events that leads the cell to divide into two daughter cells, each containing chromosomes identical to the parent cell. It is the cell cycle that leads to the formation of an entire organism from a single-cell zygote. Besides, cell division also functions in the renewal or repair of tissues in adult multicellular eukaryotes. For example, in the bone marrow, the stem cells divide to form new blood cells. Although essential for several functions, cell...
13.9K
The Cell Cycle Control System01:28

The Cell Cycle Control System

The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K